
Please try another search
Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company’s APIs are used in various therapeutic segments, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, and anti-infectives. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was incorporated in 2011 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.
Name | Age | Since | Title |
---|---|---|---|
Hirenbhai Karsanbhai Patel | 50 | 2024 | Non Executive Chairman |
Yasir Yusufali Rawjee | 59 | 2019 | CEO, MD & Director |
Vinod Naik | - | 2022 | Group VP, Head of Technical Operations & Whole Time Director |
Taruvai Laxminarayanan Easwar | - | 2021 | Non-Executive Independent Director |
Kaushikbhai Nandubhai Patel | 70 | 2024 | Additional Independent Director |
Manju Agarwal | 68 | 2020 | Non-Executive Independent Director |
Savan Godiawala | - | 2024 | Additional Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review